Tag Archives: Hepatitis C

VA Extending Hepatitis C Therapy

VA Extending Hepatitis C Therapy as its drug spend for the disease increases rapidly. The department last year allocated $696 million for new hepatitis C drugs, accounting for 17 percent of the VA’s total pharmacy budget. In fiscal 2016, which began Oct. 1, 2015, the VA expects to spend about $1 billion on hepatitis C […]

Planning a Specialty Drug Strategy Through 2020

Planning a Specialty Drug Strategy Through 2020 – Traditional approaches are not suited to managing the cost of specialty drug therapies By Gregory Judd, CEBS, and Randy Vogenberg, PhD  5/4/2015 (originally published by Society for Human Resource Management (SHRM))   The specialty drug tsunami is picking up strength and is about to come crashing down on […]

Seeking Value: Managing Specialty Medications and Medication Adherence

Amid the constant change churning the health care marketplace, employers have the opportunity to use value-based tactics to get more for their health benefits, including pharmaceutical spending that is currently the biggest driver of rising health care costs. That message was echoed by all four speakers at the Alliance Learning Circle on “Doses and Dollars: […]

John Santilli quoted in Modern Medicine: Olysio indication expanded for combo use with Sovaldi in hepatitis C

“[Hepatitis C] is a very competitive market, as a number of companies are looking to compete with Gilead’s products due to the large population of patients and the high earnings potential for drug sales,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries.  Read more here: http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/top-five-industry-challenges-2015?page=0,7

Continuation in rising costs of specialty drugs and maybe accelerate in next 1-2 years

Gilead Sciences’ ($GILD) hep C drug Sovaldi burst onto the market, impressing doctors and patients with its benefits and outraging payers and politicians with its price. It reached blockbuster status twice over in the course of a single quarter. But instead of an aberration, a new report suggests it is a reflection of a trend that has […]

Clinical trial collaborations – an idea whose time has come

The cost and time commitment to develop new drugs has increased significantly over the last few decades. A variety of factors come into play, but on average, in terms of total expenditures, it has taken from $3 to $5 billion and up to 15 years to bring a new drug to market. Even after all […]

Hepatitis C and Specialty Pharmacy Market

Express Scripts Plans a Specialty Drug Price War over new hepatitis C treatments reports a recent Bloomberg News story. The news follows the release of Gilead’s Sovaldi (sofosbuvir), which reportedly costs $1,000 per pill. Express Scripts projects that Hepatitis C drug trend will grow by 168% by 2015, so employers and health plan payers are […]

Hepatitis C and Specialty Pharmacy Market

Express Scripts Plans a Specialty Drug Price War over new hepatitis C treatments reports a recent Bloomberg News story. The news follows the release of Gilead’s Sovaldi (sofosbuvir), which reportedly costs $1,000 per pill. Express Scripts projects that Hepatitis C drug trend will grow by 168% by 2015, so employers and health plan payers are […]